Nasopharyngeal Carcinoma Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies

Nasopharyngeal Carcinoma Companies are Akeso Tiancheng, Inc, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Novartis, Jiangsu HengRui Medicine, Qilu Pharmaceutical, Akeso, Bristol-Myers Squibb, Sanofi, Innovent Biologics (Suzhou) Co. Ltd., Eli Lilly and Company, and others

(Albany, USA) DelveInsight’s “Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Nasopharyngeal Carcinoma, historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 The Nasopharyngeal Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Nasopharyngeal Carcinoma market dynamics.

The Nasopharyngeal Carcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Nasopharyngeal Carcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Nasopharyngeal Carcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Nasopharyngeal Carcinoma market.

Request for sample report @ Nasopharyngeal Carcinoma Market Forecast

Some of the key facts of the Nasopharyngeal Carcinoma Market Report

• The Nasopharyngeal Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034) 
• As per the studies of the National Health Services (NHS), men are affected about 3 times more than women by nasopharyngeal cancer 
• A higher number of patients diagnosed with Nasopharyngeal Carcinoma are above the age of 65 or older 
• The global prevalence of Nasopharyngeal Carcinoma is 1.2 persons among 100,000 people
• In the United States, the incidence of Nasopharyngeal Carcinoma is 7 cases diagnosed per 1 million people annually  
• Key Nasopharyngeal Carcinoma Companies: Akeso Tiancheng, Inc, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Novartis, Jiangsu HengRui Medicine, Qilu Pharmaceutical, Akeso, Bristol-Myers Squibb, Sanofi, Innovent Biologics (Suzhou) Co. Ltd., Eli Lilly and Company, and others 
• Key Nasopharyngeal Carcinoma Therapies: AK105, TQB2618, Gemcitabine, Zometa (zoledronic acid), SHR-1210, QL1706, Penpulimab, Nivolumab, Docetaxel, Sintilimab, Pemetrexed (Alimta), and others
• The Nasopharyngeal Carcinoma epidemiology based on gender analyzed that the prevalence of Nasopharyngeal Carcinoma is commonly more in males than females
• In April 2025, Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with at least one other prior line of therapy. Penpulimab-kcqx was developed independently by Akeso, with further development and commercialization managed through a joint venture with Chia Tai-Tianqing Pharmaceutical Group.
• In April 2025, Coherus Biosciences, Inc. announced a Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
• In March 2025, MediLink Therapeutics (Suzhou) Co., Ltd. announced results of a Randomized, Controlled, Multicenter Phase III Clinical Study of YL201 Versus Investigator's Choice of Chemotherapy in Subjects with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Failed Prior PD-(L)1 Inhibitor and At Least Two Lines of Chemotherapy
• In March 2025, Akeso announced results of a Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
• ​In June 2024, Sichuan Baili Pharmaceutical Co., Ltd. announced a Phase III Randomized Controlled Trial to Compare BL-B01D1 With Physician's Choice of Chemotherapy (Last Line) in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Previously Treated With PD-1/PD-L1 Monoclonal Antibody and at Least Two Lines of Chemotherapy (at Least One Line of Platinum-based Chemotherapy)
• On October 27, 2023, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (brand name LOQTORZI) for the treatment of nasopharyngeal carcinoma (NPC). This approval encompasses two indications:

Discover more about therapies set to grab major Nasopharyngeal Carcinoma market share @ Nasopharyngeal Carcinoma Medication and Pipeline Market

Nasopharyngeal Carcinoma Overview

The portion of the throat (nasopharynx) that connects the back of the nose to the back of the mouth is affected by a kind of head and neck cancer called nasopharyngeal carcinoma. It should not be confused with other cancers of the throat, such as oesophageal and laryngeal cancer.

Nasopharyngeal Carcinoma Epidemiology

Global incidence of nasopharyngeal carcinoma (NPC) remains significant, with GLOBOCAN reporting more than 120,000 newly diagnosed cases worldwide in 2022, including nearly 2,000 cases in the United States. In the UK, Cancer Research UK estimates that around 260 people are diagnosed with NPC annually, with men being more frequently affected than women.

Epidemiological patterns vary considerably between endemic and non-endemic regions. Research by Shah and Nagalli (2022) showed that incidence rates are below 1 case per 100,000 individuals in low-risk regions, while endemic areas report substantially higher rates, reaching 25–50 cases per 100,000 males and 15–20 cases per 100,000 females.

According to the American Cancer Society (2025), the risk of developing NPC generally increases with age, although the disease can occur across all age groups, including children. In low-incidence countries such as the United States, cases are commonly seen among young adults aged 15–24 years, decline during middle age, and rise again among older adults aged 65–79 years.

DelveInsight estimates that Japan reported nearly 700 new NPC cases in 2024. In the same year, the United States recorded approximately 64,000 new head and neck squamous cell carcinoma (HNSCC) cases, including around 2,100 nasopharyngeal HNSCC cases. Across the EU4 and the UK, Germany accounted for roughly 300 new NPC cases, while Italy reported approximately 600 cases in 2024.

Nasopharyngeal Carcinoma Epidemiology Segmentation:

The Nasopharyngeal Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Nasopharyngeal Carcinoma
• Prevalent Cases of Nasopharyngeal Carcinoma by severity
• Gender-specific Prevalence of Nasopharyngeal Carcinoma
• Diagnosed Cases of Episodic and Chronic Nasopharyngeal Carcinoma 

Nasopharyngeal Carcinoma Market  

The dynamics of the Nasopharyngeal Carcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Gemcitabine, Cisplatin, and others during the forecasted period 2020-2034. 

The Nasopharyngeal Carcinoma market is driven by increasing incidence rates in endemic regions, particularly Southeast Asia and parts of North Africa, growing awareness of early detection, and advancements in diagnostic imaging and radiotherapy techniques. The introduction of targeted therapies and immunotherapies, along with ongoing clinical research, further supports market growth.

Additionally, government initiatives, screening programs, and improving healthcare infrastructure in developing countries contribute to early diagnosis and better outcomes.

However, the market faces several barriers, including the rarity of the disease in non-endemic areas, which limits widespread research investment and awareness. High treatment costs, limited access to advanced therapies in low-income regions, and the challenge of managing recurrent or metastatic NPC also hinder growth. Furthermore, late-stage diagnosis and treatment-related toxicities remain significant obstacles to optimal patient care.

Download the report to understand which factors are driving Nasopharyngeal Carcinoma epidemiology trends @ Nasopharyngeal Carcinoma Epidemiological Insights

Nasopharyngeal Carcinoma Drugs Uptake

IAE0972 – SunHo Biopharmaceutical

IAE0972 is an EGFR-IL10 immunocytokine developed to overcome immune exhaustion associated with existing immunotherapies and improve upon the limitations of EGFR-targeted monoclonal antibodies. The therapy activates antigen-specific CD8+ T cells within the tumor microenvironment and helps restore the tumor-fighting ability of exhausted T cells by improving oxidative phosphorylation metabolism. Currently, IAE0972 in combination with chemotherapy is being investigated in Phase II/III clinical trials for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma who have failed or progressed after at least two prior systemic therapies.

GEN1160 (PRO1160) – Genmab

GEN1160 (formerly PRO1160) is a CD70-targeting topoisomerase I inhibitor designed for the treatment of multiple solid tumors and hematologic malignancies, including nasopharyngeal carcinoma. CD70 is highly expressed in several cancers, making it a promising therapeutic target. The candidate was originally developed by ProfoundBio before being acquired by Genmab in April 2024. The therapy is currently undergoing Phase I/II clinical evaluation for solid tumors, including nasopharyngeal carcinoma.

Nasopharyngeal Carcinoma Therapies and Key Companies

• AK105: Akeso Tiancheng, Inc
• TQB2618: Chia Tai Tianqing Pharmaceutical
• Gemcitabine: Hoffmann-La Roche
• Zometa (zoledronic acid): Novartis
• SHR-1210: Jiangsu HengRui Medicine
• QL1706: Qilu Pharmaceutical
• Penpulimab: Akeso
• Nivolumab: Bristol-Myers Squibb
• Docetaxel: Sanofi
• Sintilimab: Innovent Biologics (Suzhou) Co. Ltd
• Pemetrexed (Alimta): Eli Lilly and Company

Scope of the Nasopharyngeal Carcinoma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Nasopharyngeal Carcinoma Companies: Akeso Tiancheng, Inc. (HKEX: 9926), Chia Tai Tianqing Pharmaceutical (part of Sino Biopharmaceutical, HKEX: 1177), Hoffmann-La Roche (SWX: ROG), Novartis (SWX: NOVN), Jiangsu HengRui Medicine (SHA: 600276), Qilu Pharmaceutical (privately held), Akeso (HKEX: 9926), Bristol-Myers Squibb (NYSE: BMY), Sanofi (EPA: SAN), Innovent Biologics (Suzhou) Co. Ltd. (HKEX: 1801), and Eli Lilly and Company (NYSE: LLY) and others
• Key Nasopharyngeal Carcinoma Therapies: AK105, TQB2618, Gemcitabine, Zometa (zoledronic acid), SHR-1210, QL1706, Penpulimab, Nivolumab, Docetaxel, Sintilimab, Pemetrexed (Alimta), and others
• Therapeutic Assessment: Nasopharyngeal Carcinoma current marketed and Nasopharyngeal Carcinoma emerging therapies
• Nasopharyngeal Carcinoma Market Dynamics: Nasopharyngeal Carcinoma market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Nasopharyngeal Carcinoma  Market Access and Reimbursement

To know more about Nasopharyngeal Carcinoma treatment, visit @ Nasopharyngeal Carcinoma clinical trials and fda addprovals 

Table of Contents 

1. Nasopharyngeal Carcinoma Market Report Introduction

2. Executive Summary for Nasopharyngeal Carcinoma

3. SWOT analysis of Nasopharyngeal Carcinoma

4. Nasopharyngeal Carcinoma Patient Share (%) Overview at a Glance

5. Nasopharyngeal Carcinoma Market Overview at a Glance

6. Nasopharyngeal Carcinoma Disease Background and Overview

7. Nasopharyngeal Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Nasopharyngeal Carcinoma 

9. Nasopharyngeal Carcinoma Current Treatment and Medical Practices

10. Nasopharyngeal Carcinoma Unmet Needs

11. Nasopharyngeal Carcinoma Emerging Therapies

12. Nasopharyngeal Carcinoma Market Outlook

13. Country-Wise Nasopharyngeal Carcinoma Market Analysis (2020–2034)

14. Nasopharyngeal Carcinoma Market Access and Reimbursement of Therapies

15. Nasopharyngeal Carcinoma Market drivers

16. Nasopharyngeal Carcinoma Market barriers

17.  Nasopharyngeal Carcinoma Appendix

18. Nasopharyngeal Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.